-79.7%
SNAP vs GSK
+88.1%
-167.8%
-95.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.6% | -0.2% | -2.4% | -2.5% |
| 7D | -7.1% | +1.7% | -8.8% | -7.4% |
| 30D | -14.6% | +7.0% | -21.7% | -16.0% |
| 3M | -5.0% | -2.7% | -2.3% | -4.4% |
| 6M | -18.8% | +1.4% | -20.2% | -19.4% |
| YTD | -38.5% | +5.3% | -43.9% | -40.0% |
| 1Y | -38.1% | +10.6% | -48.7% | -40.4% |
| 3Y | -53.8% | +62.6% | -116.4% | -62.1% |
| 5Y | -90.7% | +41.7% | -132.4% | -92.1% |
| All | -79.7% | +88.1% | -167.8% | -84.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling